Jianxin Chen, ZhenGe Biotech chairman and CEO
Low-profile Shanghai-based CDMO secures high profile investors for 9-digit Series C
In a bid to expand R&D and manufacturing capabilities, Shanghai-based ZhenGe Biotech netted a $100 million Series C Tuesday.
With offices in Shanghai and the …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
